These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
113 related items for PubMed ID: 7915368
1. Efficacy of low-density-lipoprotein lowering with statins. Leufkens HG, Herings RM, Urquhart J. Lancet; 1994 Sep 03; 344(8923):683-4. PubMed ID: 7915368 [No Abstract] [Full Text] [Related]
2. Efficacy of low-density-lipoprotein lowering with statins. Seidel D, Cremer P. Lancet; 1994 Sep 03; 344(8923):683. PubMed ID: 7915367 [No Abstract] [Full Text] [Related]
4. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Lancet; 1994 Jun 18; 343(8912):1554-5. PubMed ID: 7911877 [No Abstract] [Full Text] [Related]
6. Reducing expenditures for statin-type lipid-lowering agents. Am J Health Syst Pharm; 1998 May 15; 55(10):995-6, 999. PubMed ID: 9606450 [No Abstract] [Full Text] [Related]
7. Lipid-lowering with statins and fibrinolytic parameters. Jovin IS, Heidinger K, Taborski U, Muller-Berghaus G. Eur Heart J; 1997 Sep 15; 18(9):1516. PubMed ID: 9458463 [No Abstract] [Full Text] [Related]
8. [Efficacy and safety of simvastatin in the treatment of hyperlipidemia in uremic patients undergoing hemodialysis treatment]. Fiorini F, Patrone E, Ardu F, Castelluccio A. Minerva Urol Nefrol; 1992 Sep 15; 44(2):165-8. PubMed ID: 1411867 [Abstract] [Full Text] [Related]
9. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Miller M, Dolinar C, Cromwell W, Otvos JD. Am J Cardiol; 2001 Jan 15; 87(2):232-4, A9. PubMed ID: 11152850 [Abstract] [Full Text] [Related]
11. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia. Grundy SM. Am J Cardiol; 1998 Feb 26; 81(4A):1B-6B. PubMed ID: 9526806 [No Abstract] [Full Text] [Related]
13. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias]. Carmena R. Rev Esp Cardiol; 1995 Jan 26; 48(1):59-65. PubMed ID: 7878284 [No Abstract] [Full Text] [Related]
14. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Ide H, Fujiya S, Aanuma Y, Agishi Y. Clin Ther; 1990 Jan 26; 12(5):410-20. PubMed ID: 2268863 [Abstract] [Full Text] [Related]
15. Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients. Furman A, Meier JL, Malmstrom RA, Lopez JR, Schaefer S. Am J Manag Care; 2011 Jan 26; 17(8):538-44. PubMed ID: 21851141 [Abstract] [Full Text] [Related]
16. Dosing and administration schedule of HMG CoA reductase inhibitors. Sweany AE. Heart Dis Stroke; 1993 Jan 26; 2(3):263. PubMed ID: 8179691 [No Abstract] [Full Text] [Related]
18. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. French JK, White HD, Greaves SC. N Z Med J; 1990 Feb 14; 103(883):41-3. PubMed ID: 2304688 [Abstract] [Full Text] [Related]
19. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Davidson MH, Macariola-Coad JR, McDonald AM, Maki KC, Hall HA. Am J Cardiol; 1997 Sep 15; 80(6):797-8. PubMed ID: 9315596 [Abstract] [Full Text] [Related]
20. Cost-benefit analysis of lipid lowering therapy. Jönsson B, Johannesson M. Eur Heart J; 1997 Jan 15; 18(1):165-6. PubMed ID: 9049529 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]